Evaluation of Biosynthetic Constructs to Replace Donor Corneas

NCT ID: NCT02374723

Last Updated: 2016-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Constructs made from cross-linked Human Recombinant Collagen type III are being used instead of human donor corneas in 6 patients at Deep anterior lamellar cornea grafting. Six patients serve as controls and are receiving human donor corneas using the same surgical technique. The twelve patients will be recruited from the local waiting list for patients to be undergoing corneal grafting. If the patients meet the inclusion criteria and agree to participate following oral and written consent, they will be randomized to either group. The patients will be followed for 12 months and documented with OCT, In Vivo Confocal Microscopy, slit lamp photography a o. The study is planned as a safety study with initial efficacy documentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

12 patients will be recruited from the waitinglist for corneal transplantation.The will all be of the age of 18 years or older and capable of making their own decisions. Their medical history and present medication is reveiwed and they undergo a thorough ophthalmological examination in order to find out if they meet the inclusion criteria and create baseline values for the study. Their general health or medication should not affect the cornea or ocular surface. The Eye should be healthy with the exception of the disease indication for corneal grafting. The corneal endothelium should be healthy. Any opacification in the eye to be grafted should not reach the Descemets membrane. Visual acuity in the fellow eye should be good. If these criteria are met the patient recieve oral and written information of the study. If they agree to participate they will be randomized to either recieve biosynthetic corneas ( 6 patients) or they will recieve a donated cornea ( 6 patients) . They will be scheduled for surgery within 2 weeks from the examination irrespective if they participate in the study or not.

The surgery will be anterior deep lamellar using the femtosecond laser to do the patient cut. The laser cut wil be done in topical anaaestesi. The remaining surgery with either be performed in local oor general anaestesia according to the patients wish. The diameter of the cut will be 7 mm in diameter. The graft material will be punched to a diameter of 7.25 mm. The thickness of the material will be 500 µm . An amniotic membrane will be placed on the top of the biosynthetic material and sutured with single stiches together with the graft.A bandage lens will be placed . The donated corneas will be sutured with singled about 8 stiches.

The biosynthetic corneas will recieve topical antibiotics and dexametasone for 8 weeks when the sutures, remnants of the amniotic membrane and the bandage lens is removed. The donated corneas will recieve topical dexametasone for 5 months and the sutures will be removed after 6 months.

The check-up Schedule will be at 1 day,1,2 weeks,1,,2 months and extra when needed.The protocol in these check-ups will be descriptive and the exyes will be documented with slit lamp photography. Epitelialisation will be monitored with fluorescein staining.

At the 3,6,9 and12 months will be extensive and the same in both groups. UCVA and BSCVA will be measured and also BCLCVA at 12 months. Corrneal topography,thickness sensitivity,tear production Visante OCT and slit- lamp photography will be performed. Tear samples will be taken also form earlier check-ups for proteomic analysis. In vivo confocal microscopy will be performed. The different examination with few exceptions can all be presented in results that can be quantified and statistically analysed.

The CRFs and the adverse report forms will be filled out both on computer forms and on paper.

The safety outcome criteria are: Good engraftment, maintained integrity of the graft, epithelialisation, transparency,no induced inflammation,no induced vasculatisation.

The preliminary efficacy criteria are: UCVA,BSCVA and BCLCVA

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corneal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NuCornea (Biosynthetic corneas)

6 patients will receive biosynthetic corneas when undergoing corneal transplantation

Group Type EXPERIMENTAL

NuCornea

Intervention Type DEVICE

Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea

Donated human corneas

6 patients will receive a donated human cornea when undergoing corneal transplantation

Group Type ACTIVE_COMPARATOR

donated human corneas

Intervention Type DEVICE

Deep anterior lamellar corneal transplantation with a donated cornea as graft material.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NuCornea

Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea

Intervention Type DEVICE

donated human corneas

Deep anterior lamellar corneal transplantation with a donated cornea as graft material.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Biosynthetic cornea

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Indication for Deep anterior lamellar corneal transplantation.
* No topical Eye medication.

Exclusion Criteria

* No Eye disease other than the indication for the corneal graft.
* No general disease that might affect the cornea.
* No general medication that might affect the cornea.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Swedish Research Council

OTHER_GOV

Sponsor Role collaborator

Region Östergötland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Per.Fagerholm

professor,MD,PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Per Fagerholm, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Dept of Ophthalmology, University Hospital, Linköping,Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DNr52120125706

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cornea Preservation Time Study
NCT01537393 COMPLETED PHASE4